We expect investors to focus on updates related to Sol-Gel Technologies, Ltd.’s SLGL ability to regain compliance with the recent Nasdaq requirement and other pipeline development activities when it...
Mori Arkin appointed interim CEO; Sol-Gel reports ongoing clinical trials and recent financial developments.Quiver AI SummarySol-Gel Technologies, Ltd. announced that shareholders approved the appointment...
Prescription volumes to date indicate strong uptake, similar to successful dermatology launches Sol-Gel receives $3.5 million milestone payment from...
FDA approval for EPSOLAY® (benzoyl peroxide, cream, 5%) represents Sol-Gel’s second approved product within less than a year; EPSOLAY is patent protected...
EPSOLAY (benzoyl peroxide, cream, 5%) utilizes Sol-Gel’s proprietary microencapsulation technology for the treatment of inflammatory lesions of rosacea and...
TWYNEO is the first-ever tretinoin and benzoyl peroxide combination to treat facial acneSol-Gel’s U.S. commercialization partner, Galderma, launched...
Galderma launched TWYNEO® at the Annual Meetings of the American Academy of Dermatology, March 25-29, 2022 in Boston, MA. TWYNEO will be commercially...
TWYNEO will be officially launched for commercial availability in Spring 2022....